IR-Center Handelsblatt
Unternehmenssuche:

Edison Investment Research Limited (UK)

News Detail

EQS-News News vom 02.05.2017

Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)

EQS-News: Edison Investment Research Limited / Key word(s): Research Update

02-May-2017 / 12:02 GMT/BST


London, UK, 2 May 2017

Edison issues outlook on Oryzon Genomics (ORY)

Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016, ORY-1001, an LSD1 inhibitor, is now in Roche's hands and the company is focusing on its newer programmes: clinical-stage ORY-2001, a dual LSD1/MAOB inhibitor for neurodegenerative diseases and ORY-3001, a selective LSD1 inhibitor, in advanced preclinical studies in non-cancer areas. We have incorporated the recent EUR18m equity raise into our valuation, which has increased to EUR308m.

We have increased our valuation of Oryzon from EUR266m to EUR308m or EUR9.0/share (from EUR9.3/share) on the back of the recent financing round and higher success probability for AD. The main potential catalysts over the next 12-24 months are progress in the SCLC trial run by Roche, initiation of Phase II trials in neurodegenerative disorders with ORY-2001, new preclinical candidates entering the clinic and delivering first human data.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv


Dissemination of a UK FINANCIAL NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

show this